Dexcom (DXCM) Q2 2025 10-Q Quarterly Report
Filed: Jul 30, 2025Period ending Jun 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Dexcom (DXCM) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Jul 30, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Dexcom Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $1.16B, up 15% YoY from $1.00B in Q2 2024, driven by disposable sensor volume growth
- • Operating margin 18.4% vs 15.7% YoY, operating income $212.6M up 35% reflecting improved profitability
- • Best segment: Disposable sensors ~97% of revenue, increased volume adding 500k-600k customers; worst: Reusable Hardware down to 3% from 6% of revenue
- • Cash and equivalents $2.93B, operating cash flow $303M increased 8% YoY
- • Near-term headwinds: Pricing pressure from rebates and channel mix, gross margin declined from 62.4% to 59.5% due to supply inefficiencies and product mix changes
Risk Factors
- • No newly added risk factors this quarter; risk section supplements and supersedes 2024 10-K risks
- • No material changes to previously disclosed risks; 10-K risk factors remain primary disclosures
- • No updated regulatory, legal, or compliance risks specified beyond those in 2024 10-K
- • No operational or market risk updates; previous supply chain and competition risks continue
- • No new financial risks related to liquidity, debt, currency, or concentration reported this quarter
Dexcom Q2 2025 Quarterly FinancialsXBRL
Revenue
$1.2B
▲ +15.2% YoY▲ +11.7% QoQ
Net Income
$180M
▲ +25.3% YoY▲ +70.6% QoQ
Gross Margin
59.5%
▼ -287bp YoY▲ +267bp QoQ
Operating Margin
18.4%
▲ +264bp YoY▲ +547bp QoQ
Net Margin
15.5%
▲ +125bp YoY▲ +537bp QoQ
EPS (Diluted)
$0.44
▲ +25.7% YoY▲ +63.0% QoQ
Operating Cash Flow
$303M
▲ +8.4% YoY▲ +64.9% QoQ
Source: XBRL data from Dexcom Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Dexcom Quarterly Reports
Get deeper insights on Dexcom
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.